| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients
|
Honing, J.
|
|
|
25 |
3 |
p. 638-643
|
article
|
| 2 |
An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients
|
Regierer, A.C.
|
|
|
25 |
3 |
p. 633-638
|
article
|
| 3 |
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG †
|
Smorenburg, C.H.
|
|
|
25 |
3 |
p. 599-605
|
article
|
| 4 |
Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials
|
Gandini, S.
|
|
|
25 |
3 |
p. 618-623
|
article
|
| 5 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer
|
Arnedos, M.
|
|
|
25 |
3 |
p. 605-610
|
article
|
| 6 |
Breaking bad news–what patients want and what they get: evaluating the SPIKES protocol in Germany
|
Seifart, C.
|
|
|
25 |
3 |
p. 707-711
|
article
|
| 7 |
Cancer evolution: the final frontier of precision medicine?
|
Swanton, Charles
|
|
|
25 |
3 |
p. 549-551
|
article
|
| 8 |
Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study
|
Houvenaeghel, G.
|
|
|
25 |
3 |
p. 623-628
|
article
|
| 9 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
|
Vermorken, J.B.
|
|
|
25 |
3 |
p. 682-688
|
article
|
| 10 |
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
|
Leibowitz-Amit, R.
|
|
|
25 |
3 |
p. 657-662
|
article
|
| 11 |
Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer—a dose–response meta-analysis
|
Discacciati, A.
|
|
|
25 |
3 |
p. 584-591
|
article
|
| 12 |
Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
|
Schilling, B.
|
|
|
25 |
3 |
p. 747-753
|
article
|
| 13 |
Editorial board
|
|
|
|
25 |
3 |
p. ii-iii
|
article
|
| 14 |
Effect of marital status on treatment and survival of extremity soft tissue sarcoma
|
Alamanda, V.K.
|
|
|
25 |
3 |
p. 725-729
|
article
|
| 15 |
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review
|
Puts, M.T.E.
|
|
|
25 |
3 |
p. 564-577
|
article
|
| 16 |
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
|
|
|
|
25 |
3 |
p. 757
|
article
|
| 17 |
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
|
Schadendorf, D.
|
|
|
25 |
3 |
p. 700-706
|
article
|
| 18 |
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
|
Dienstmann, R.
|
|
|
25 |
3 |
p. 552-563
|
article
|
| 19 |
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
|
Leyvraz, S.
|
|
|
25 |
3 |
p. 742-746
|
article
|
| 20 |
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
|
Kasper, B.
|
|
|
25 |
3 |
p. 719-724
|
article
|
| 21 |
Metastatic pattern in colorectal cancer is strongly influenced by histological subtype
|
Hugen, N.
|
|
|
25 |
3 |
p. 651-657
|
article
|
| 22 |
On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? †
|
Hamaker, M.E.
|
|
|
25 |
3 |
p. 675-681
|
article
|
| 23 |
Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups
|
|
|
|
25 |
3 |
p. 756
|
article
|
| 24 |
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
|
Baselga, J.
|
|
|
25 |
3 |
p. 592-598
|
article
|
| 25 |
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC)
|
Fury, M.G.
|
|
|
25 |
3 |
p. 689-694
|
article
|
| 26 |
Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study
|
Ørsted, D.D
|
|
|
25 |
3 |
p. 712-718
|
article
|
| 27 |
Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer—a problem still to be solved
|
Schmidt, M.
|
|
|
25 |
3 |
p. 754
|
article
|
| 28 |
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
|
Dieci, M.V.
|
|
|
25 |
3 |
p. 611-618
|
article
|
| 29 |
Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
|
Goldhirsch, A.
|
|
|
25 |
3 |
p. 755
|
article
|
| 30 |
Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
|
Toulmonde, M.
|
|
|
25 |
3 |
p. 735-742
|
article
|
| 31 |
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
|
Toulmonde, M.
|
|
|
25 |
3 |
p. 730-734
|
article
|
| 32 |
Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group
|
Gronchi, A.
|
|
|
25 |
3 |
p. 578-583
|
article
|
| 33 |
Table of Contents
|
|
|
|
25 |
3 |
p. iv-vi
|
article
|
| 34 |
The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects †
|
Wöckel, A.
|
|
|
25 |
3 |
p. 628-632
|
article
|
| 35 |
The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer
|
Park, J.H.
|
|
|
25 |
3 |
p. 644-651
|
article
|
| 36 |
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience
|
Hong, F.
|
|
|
25 |
3 |
p. 669-674
|
article
|
| 37 |
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
|
Voss, M.H.
|
|
|
25 |
3 |
p. 663-668
|
article
|
| 38 |
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis
|
Bossi, P.
|
|
|
25 |
3 |
p. 694-699
|
article
|
Journal description